The following Powerpoint is copy and pasted from the June 12th 8-k...
3 great videos to watch on Low Dose Naltrexone
https://www.youtube.com/watch?v=YtDxpA52NvU (4 mins, very uplifting encouraging video about a woman's story on LDN)
https://www.youtube.com/watch?v=FDCn0JWv6Io (59 mins; very informative documentary telling the story of LDN)
https://www.youtube.com/watch?v=rll1A3aFhjc (79 mins; "[the late] Dr Bihari [the pioneer of low dose naltrexone] is Interviewed about Low Dose Naltrexone LDN for Normalizing Immune System Function")
2 great books on Low Dose Naltrexone
Other Important Links:
8-k from 4/27/16: LDN is approved in Nigeria
8-k from 5/23/17: LDN gets marketing approval in Nigeria
8-k from 4/13/17: Debt restructuring to eliminate a very "toxic" note. This 8-k may have marked the inflection point on the graph of IMUN
Letter of Intent from Fidson Healthcare PLC - this was a publishing from August 2015 that popped IMUN to just over $0.30 briefly
The medicine your doctor never told you about (but should have)
Stock Quote of Fidson Healthcare PLC - IMUN's partner for marketing / distribution in Nigeria - notice how the ticker has shot up since April on NO PUBLISHED NEWS
Low-Dose Naltrexone (LDN): One of the RARE Drugs that Actually Helps Your Body to Heal Itself
My experience with Low Dose Naltrexone By David Gluck, MD (the story of a lifelong friend of Dr. Bernard Bihari, the pioneer of LDN)
11 Facts about HIV in Africa
We now have a NEW Senior Regulatory Advisor (see last page of powerpoint) who is ALSO the Senior Regulatory Officer for the GATES FOUNDATION!
- 37 North Orange Ave
Orlando, FL 32801
| || || || |
| ||Authorized Shares ||500,000,000 ||a/o May 31, 2017 |
| ||Outstanding Shares ||313,406,831 ||a/o May 31, 2017 |
Patent and Subsidiary Acquisition
The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000.
- Cytocom. Cytocom Inc. is our affiliate clinical-stage pharmaceutical company focused on advancing IRT-103 (US FDA designator for ‘Lodonal’). It is responsible for the development of our patented therapies with the FDA and EMA. It will lead the US and EMA (“European Medical Association”) clinical trials on IRT-103 including for Crohn’s disease. We have quietly made solid progress advancing Cytocom toward our next major goal, which is to finance it as a standalone entity, possibly publicly traded depending on its capital market valuation and profile.
The following link contains an important Powerpoint presentation. Page 8 of the presentation is a key page. As of March 31, 2017, IMUN owns a 13.3% stake in Cytocom, which has been diluted down from an original 55% stake when the spinoff occured in 2014.
- Advance IMUN’s Growing Drug Pipeline. We have started our second clinical for Lodonal as an adjunct treatment for cancer in Malawi, which is slated for completion in mid-2017, with results to be published in the second half of the year. We also plan a bridging trial with MENK for cancer in Nigeria, capitalizing on our strong relationship with NAFDAC -– amongst other clinical trials being developed or planned.
Increase the IP Portfolio. We will continue to protect the value of our clinical research by building intellectual property value as an asset, thus erecting barriers to entry. We filed two new patents surrounding Lodonal in 2016.
Establish a Solid Base of Operations in China. Our Chief Science Officer and Vice Director of the Institute of Immunology, China Medical University in Shenyang, China have been treating patients with MENK and our new cocktail therapy throughout 2016 with positive results. Now that our patents are filed for the cocktail, we plan to publish results in 2017 as part of a larger initiative to advance clinical trials, and establish a solid beachhead in this nation of 1.4 billion people as a gateway to Asia. Our goal is to open our cancer clinic in China to treat patients by year-end 2017.
Reinforce the IMUN Management Team and Boards. As we grow, and our opportunities increase, we plan to add highly accomplished executives to our management team and boards from the fields of science, medicine, pharmaceuticals and finance to help drive the Company’s growth.